

Point of care will change the CDMO business structure from Centralise to De-Centralise cell manufacturing

November 1, 2025 | Opinion | By Ayesha Siddiqui

With Japan emerging as a hub for regenerative medicine innovation, Teijin Regenet, a Teijin Group company, has become a key player driving next-generation manufacturing and CDMO growth. In 2025, the company signed a series of partnerships, including a global licensing deal with the UK's Elevara Medicines Limited for a rheumatoid arthritis drug candidate, and a collaboration with Cell Therapies to expand access to cell and gene therapies (CGT) across Japan and the Asia-Pacific (APAC). Teijin Group companies also received government subsidies to further strengthen their regenerative medicine manufacturing capabilities. In an interaction with BioSpectrum Asia, Takeshi Hosoyama, Deputy President, Teijin Regenet, discusses how the company is adapting its CDMO model to meet the evolving needs of partners, its strategic priorities for expansion, and the industry trends shaping the future of regenerative medicine in Japan and globally.



With the CDMO segment seeing rapid growth, how would you describe the changing profile of your clients, and how is Teijin CDMO adapting to meet their evolving needs?

Teijin CDMO can provide a cell manufacturing service to early-stage startup companies to global pharmaceutical giants in the CGT and regenerative medicine fields, as part of our total solution.

What are your key strategic priorities as you expand both regenerative medicine manufacturing and CDMO services?

We operate two distinct business units: J-TEC, which handles the distribution and manufacturing of regenerative medicine products, and Teijin Regenet, which serves as an ex-vivo CDMO. It means to enter a broad range business field like any kind of epidermal injury, refractory eye disease, oncology and any malignancy. That is our clear advantage to competitors, and we can also collaborate with overseas partners.

How are you leveraging automation, digitalisation, and AI to strengthen manufacturing efficiency and quality?

We are developing systems to monitor and realise cell health conditions during the manufacturing process and to manage not only clinical data but also inventory and various types of data through our advanced system. We hope this system will be set in each hospital for autologous cell therapy as PoC.

Teijin CDMO works closely with academic and industry partners. How have these collaborations shaped your innovation and operational capabilities?

Our R&D and Business Development teams always share information obtained from academic and industry partners. We can make new business initiatives using this external information, because our organisation communicates well across divisions.

As demand for CGT manufacturing grows across APAC, how do you view the region's market potential and Teijin CDMO's role within it?

Japan is the third-largest medical business market and Teijin offers advanced medical treatments and clinical expertise. Moreover, we already had some Asian CDMO partners. We will play a central role in bridging the APAC and Japanese markets.

What industry trends do you expect will most influence the regenerative medicine and CDMO landscape?

Point of care will change the CDMO business structure from Centralise to De-Centralise cell manufacturing.

What are your long-term goals for Teijin CDMO?

We believe we can become a global leader, leveraging Japanese smart technology and our unique strategy. We can use our great network of KOLs such as the Japanese KOLs who specialise in iPSC and CAR-T.

Ayesha Siddiqui